You are here

Worldwide Research and Development

Welcome to Pfizer Worldwide Research & Development (WRD), where strategic partnership is a mission of our effort to deliver important medicines and vaccines to people in need across the globe.

As the world's leading biopharmaceutical company, Pfizer is proud to offer you access to our world-class research scientists, our global network of external research collaborations, and our industry-leading manufacturing and commercial capabilities.

Combining your science, tools and technologies with Pfizer's expertise in small molecule and biologic design and development could hold the key to breakthrough therapies for patients worldwide.

We are eager to explore the possibilities of partnership and invite you to closely review this website.

Cardiovascular & Metabolic Diseases

The current projections for growth in the prevalence of diabetes threaten to create a global public health crisis. WHO predicts that the worldwide prevalence of diabetes will grow from 171 million in 2000 to 373 million by 2030.

Inflammation & Remodeling

Neuroscience

In the US today, 7 of the 10 leading causes of disability are neurological and psychiatric disorders. To meet these patient needs, Pfizer is taking a bold leadership approach that will evolve from dealing with symptoms to modifying diseases, where scientifically feasible.

Oncology

Pfizer's Oncology Research Unit (ORU) strives to advance the frontiers of cancer biology and to translate this knowledge into high-impact medicines for cancer patients. The ORU comprises four pillars: Tumor Cell Biology; Bioconjugates Discovery and Development; Precision Medicine; and Integrative Biology and Biochemistry.

Rare Diseases

Pfizer's Rare Disease Research Unit (RDRU) is adopting an innovative and collaborative approach to the development of new medicines whereby it looks to develop strategic partnerships with academic and commercial enterprises to create novel therapeutics across the spectrum of rare diseases.

Vaccines

Biologics Product & Process Development

WRD Pharmaceutical Sciences envisions a network of strategic partnerships integral to its biologics technology initiatives, which include biopharmaceutical and vaccine development and manufacturing and prokaryotic expression to augment core competencies.

Biotherapeutics Discovery

Pfizer strives to become the leading biotherapeutics company by building on internal expertise and fostering strategic partnerships to access the best technologies with patent protection and technical capabilities that provide a competitive advantage.

Drug Safety

Pfizer's Drug Safety R&D group develops and applies the skills, experience and scientific tools necessary for safety assessment and risk management of targets and compounds across the research, development and commercial phases of drug development.

Epigenetics

Modification of epigenetic signaling has the potential to serve as a new route in to the treatment of human diseases, including a range of chronic and life-threatening conditions. Epigenomic profiling may form a component of successful Precision Medicine strategies, for conditions with epigenetic and non-epigenetic treatments.

Pharmacokinetics, Dynamics & Metabolism (PDM)

PDM is focused on the development of innovative small and large molecule therapies through an improved understanding of targets, pathways and modeling for preclinical efficacy, discrete toxicity, and safety biomarkers.

Precision Medicine

Precision Medicine is an approach to discovering and developing medicines and vaccines that deliver superior outcomes for patients, by integrating clinical and molecular information to understand the biological basis of disease.

Rinat

Rinat was acquired by Pfizer in 2006 and is operated as an independent biotechnology unit within Pfizer's Worldwide R&D group. Rinat focuses on antibody-based therapeutics across all disease areas of interest to Pfizer.